

# Hyon E Choy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1846278/publications.pdf>

Version: 2024-02-01

29  
papers

1,966  
citations

430442

18  
h-index

476904

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2377  
citing authors

#	ARTICLE	IF	CITATIONS
1	Two-step enhanced cancer immunotherapy with engineered <i>Salmonella typhimurium</i> secreting heterologous flagellin. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	373
2	Genetically Engineered <i>Salmonella typhimurium</i> as an Imageable Therapeutic Probe for Cancer. <i>Cancer Research</i> , 2010, 70, 18-23.	0.4	187
3	<i>Salmonella typhimurium</i> Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1 $\beta$ . <i>Theranostics</i> , 2015, 5, 1328-1342.	4.6	142
4	ppGpp-dependent Stationary Phase Induction of Genes on <i>Salmonella</i> Pathogenicity Island 1. <i>Journal of Biological Chemistry</i> , 2004, 279, 34183-34190.	1.6	129
5	GABAergic signaling linked to autophagy enhances host protection against intracellular bacterial infections. <i>Nature Communications</i> , 2018, 9, 4184.	5.8	128
6	Inverse agonist of estrogen-related receptor $\beta$ controls <i>Salmonella typhimurium</i> infection by modulating host iron homeostasis. <i>Nature Medicine</i> , 2014, 20, 419-424.	15.2	127
7	DNA looping-mediated repression by histone-like protein H-NS: specific requirement of E $\sigma$ 70 as a cofactor for looping. <i>Genes and Development</i> , 2005, 19, 2388-2398.	2.7	124
8	RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated <i>Salmonella</i> -mediated Cancer Therapy. <i>Theranostics</i> , 2016, 6, 1672-1682.	4.6	107
9	Immune response induced by <i>Salmonella typhimurium</i> defective in ppGpp synthesis. <i>Vaccine</i> , 2006, 24, 2027-2034.	1.7	95
10	Histone-like protein HU as a specific transcriptional regulator: co-factor role in repression of gal transcription by GAL repressor. <i>Genes To Cells</i> , 1996, 1, 179-188.	0.5	89
11	Anti-Tumoral Effect of the Mitochondrial Target Domain of Noxa Delivered by an Engineered <i>Salmonella typhimurium</i> . <i>PLoS ONE</i> , 2014, 9, e80050.	1.1	71
12	Anti-tumor activity of an immunotoxin (TGF $\beta$ -PE38) delivered by attenuated <i>Salmonella typhimurium</i> . <i>Oncotarget</i> , 2017, 8, 37550-37560.	0.8	53
13	The hepcidin-ferroportin axis controls the iron content of <i>Salmonella</i> -containing vacuoles in macrophages. <i>Nature Communications</i> , 2018, 9, 2091.	5.8	51
14	Cyp1a reporter zebrafish reveals target tissues for dioxin. <i>Aquatic Toxicology</i> , 2013, 134-135, 57-65.	1.9	49
15	L-Asparaginase delivered by <i>Salmonella typhimurium</i> suppresses solid tumors. <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15007.	2.0	38
16	Gene silencing by H-NS from distal DNA site. <i>Molecular Microbiology</i> , 2012, 86, 707-719.	1.2	37
17	Engineering and Visualization of Bacteria for Targeting Infarcted Myocardium. <i>Molecular Therapy</i> , 2011, 19, 951-959.	3.7	35
18	Factors influencing preferential utilization of RNA polymerase containing sigma-38 in stationary-phase gene expression in <i>Escherichia coli</i> . <i>Journal of Microbiology</i> , 2004, 42, 103-10.	1.3	21

#	ARTICLE	IF	CITATIONS
19	A Novel Balanced-Lethal Host-Vector System Based on glmS. PLoS ONE, 2013, 8, e60511.	1.1	18
20	Development of Oxytolerant Salmonella typhimurium Using Radiation Mutation Technology (RMT) for Cancer Therapy. Scientific Reports, 2020, 10, 3764.	1.6	16
21	DNA looping-dependent autorepression of <i>LEE1</i> P1 promoters by Ler in enteropathogenic <i>Escherichia coli</i> (EPEC). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2586-95.	3.3	15
22	Cell mass-dependent expression of an anticancer protein drug by tumor-targeted <i>Salmonella</i> . Oncotarget, 2018, 9, 8548-8559.	0.8	13
23	ppGpp-mediated stationary phase induction of the genes encoded by horizontally acquired pathogenicity islands and cob/pdu locus in <i>Salmonella enterica</i> serovar Typhimurium. Journal of Microbiology, 2010, 48, 89-95.	1.3	11
24	Functional validation of novel MKS3/TMEM67 mutations in COACH syndrome. Scientific Reports, 2017, 7, 10222.	1.6	9
25	An unusual feature associated with <i>LEE1</i> P1 promoters in enteropathogenic <i>Escherichia coli</i> (EPEC). Molecular Microbiology, 2012, 83, 612-622.	1.2	8
26	Identification of high-specificity H-NS binding site in <i>LEE5</i> promoter of enteropathogenic <i>Escherichia coli</i> (EPEC). Journal of Microbiology, 2014, 52, 626-629.	1.3	8
27	Reiterative transcription initiation from galP2 promoter of <i>Escherichia coli</i> . Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2000, 1491, 185-195.	2.4	7
28	Effect of promoter-upstream sequence on $\lambda$ 38-dependent stationary phase gene transcription. Journal of Microbiology, 2015, 53, 250-255.	1.3	3
29	Amino acid residues in the Ler protein critical for derepression of the <i>LEE5</i> promoter in enteropathogenic <i>E. coli</i> . Journal of Microbiology, 2016, 54, 559-564.	1.3	2